The Medicines Company to Be Acquired by Novartis in $9.7 Billion Deal

Paul, Weiss is advising The Medicines Company in its all-cash $9.7 billion acquisition by Swiss pharmaceutical giant Novartis AG. Under the terms of the agreement, Novartis agreed to pay $85 per share, representing a 45 percent premium to its unaffected share price and a 57 percent premium to its unaffected one-week average price.

The Paul, Weiss team includes, among others, corporate partners Scott Barshay, Jeffrey Marell, Manuel Frey and John Kennedy and counsel Patricia Vaz de Almeida; employee benefits partner Jean McLoughlin; intellectual property partner Chuck Googe; real estate partner Peter Fisch; tax partner Jeffrey Samuels; international trade counsel Richard Elliott; antitrust counsel Marta Kelly; and environmental counsel William O’Brien.